{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-031324","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.211933+00:00","generated_at":"2026-05-25T16:22:10.231852+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Perspective Therapeutics updates corporate presentation highlighting pipeline progress and clinical data","bullets":["[212Pb]VMT-α-NET Phase 1/2a for neuroendocrine tumors shows anti-tumor activity with no renal decline.","Melanoma program [212Pb]VMT01 Phase 1/2a ongoing; safety profile detailed in presentation.","PSV359 targeting FAP-α active on tumor and stroma; pre-targeting platform also described.","On-demand order fulfillment at regional sites as part of supply chain and manufacturing infrastructure."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-031324","json":"https://secwatch.observer/filing/0000950170-25-031324.json","markdown":"https://secwatch.observer/filing/0000950170-25-031324.md","text":"https://secwatch.observer/filing/0000950170-25-031324.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017025031324/0000950170-25-031324-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017025031324/catx-20250303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T16:22:10.231852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}